US5359068A - Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one - Google Patents

Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one Download PDF

Info

Publication number
US5359068A
US5359068A US08/083,429 US8342993A US5359068A US 5359068 A US5359068 A US 5359068A US 8342993 A US8342993 A US 8342993A US 5359068 A US5359068 A US 5359068A
Authority
US
United States
Prior art keywords
compound
formula
alkyl
treating
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/083,429
Inventor
Frank J. Urban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Assigned to PFIZER INC reassignment PFIZER INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: URBAN, FRANK J.
Priority to US08/083,429 priority Critical patent/US5359068A/en
Assigned to PFIZER INC. reassignment PFIZER INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: URBAN, FRANK JOHN
Priority to JP7502611A priority patent/JP2667987B2/en
Priority to DE69434020T priority patent/DE69434020T2/en
Priority to DK94910016T priority patent/DK0706524T3/en
Priority to ES94910016T priority patent/ES2227524T3/en
Priority to PT94910016T priority patent/PT706524E/en
Priority to CA002166203A priority patent/CA2166203C/en
Priority to PCT/IB1994/000061 priority patent/WO1995000510A1/en
Priority to EP94910016A priority patent/EP0706524B1/en
Priority to AT94910016T priority patent/ATE277041T1/en
Publication of US5359068A publication Critical patent/US5359068A/en
Application granted granted Critical
Priority to FI956279A priority patent/FI119372B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to processes and intermediates for the its preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one is useful in the treatment of psychotic disorders.
  • the present invention provides a process for preparing the compound of the formula ##STR3## which comprises treating a compound of the formula ##STR4## wherein R 2 is hydrogen, CN or CO 2 R 1 and R 1 is hydrogen or (C 1 -C 6 )alkyl with a reducing agent with the proviso that when R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl the product of the reduction is heated with an acid.
  • the invention also provides a process for preparing a compound of the formula II
  • R 2 and R 1 are both hydrogen by heating the compound of the formula II wherein R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 in the presence of an aqueous acid:
  • R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 by treating the compound of the formula ##STR7## with a compound of the formula R 2 --CH 2 --CO 2 R 1 , wherein R 2 is CN or CO 2 R 1 , respectively, and R 1 is (C 1 -C 6 )alkyl in the presence of a base.
  • the invention provides a process for preparing the compound of the formula III by treating the compound of the formula ##STR8## with a reducing agent.
  • a process for preparing the compound of formula IV which comprises treating the compound of the formula ##STR9## with the compound of the formula ##STR10## in the presence of a (C 1 -C 6 ) alkanoic acid.
  • Another aspect of the invention provides a process for preparing the compound of the formula V which comprises treating a compound of the formula ##STR11## with an enamine forming compound selected from the group consisting of t-butoxybis(dimethylamino)methane and dimethylformamide dialkylacetals in an inert solvent.
  • Yet another aspect of the invention provides a process for preparing a compound of the formula VII by treating a compound of the formula ##STR12## wherein R 2 is CO 2 R 1 or CN and R 1 is (C 1 -C 6 )alkyl with an acid at an elevated temperature.
  • a process for preparing a compound of the formula VIII which comprises treating the compound of the formula ##STR13## with a compound of the formula R 2 --CH 2 --CO 2 R 1 wherein R 2 is CO 2 R 1 or CN and R 1 is (C 1 -C 6 )alkyl in the presence of a base.
  • Another aspect of the invention provides a process for preparing the compound of the formula IX which comprises treating the compound of the formula ##STR14## with the compound of the formula ##STR15## in the presence of (CH 3 CO 2 ) 3 NaBH and acetic acid.
  • Another aspect of the invention provides a process for preparing the compound of the formula ##STR16## which comprises the steps of
  • step 4) treating the product of step 3) with an acid at an elevated temperature to form a the compound of formula II wherein R 2 and R 1 are both hydrogen;
  • step 5 treating the product of step 4 with a (C 1 -C 6 )alkanol in the presence of an acidic esterification catalyst to form the compound of formula II wherein R 2 is hydrogen and R 1 is (C 1 -C 6 )alkyl; or
  • a compound of the formula II wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl is treated with a reducing agent and the resulting product is heated with an acid to prepare compound of formula I.
  • a reaction inert solvent Suitable reducing agents are sodium hydrosulfite, hydrogen in the presence of a hydrogenation catalyst, iron in acetic acid, zinc and CaCl 2 in acetic acid and NaH 2 PO 2 in the presence of Pd/C.
  • a preferred reducing agent is sodium hydrosulfite.
  • the temperature of the reduction stage is from about 10° to about 100° C.
  • reaction temperature is preferably from about 65° to about 80° C.
  • the temperature at the acid treatment stage is from about 50° to about 110° C.
  • Acids which are useful in this stage are strong mineral acids such as concentrated hydrochloric and 6N sulfuric acids.
  • Suitable solvents are water and water miscible solvents such as (C 1 -C 6 )alkanols, tetrahydrofuran (THF) and dioxane and mixtures thereof.
  • a compound of formula II wherein R 2 is hydrogen and R 1 is hydrogen or (C 1 -C 6 )alkyl is converted to the compound of formula I by treatment with a reducing agent. Suitable conditions for the reduction are indicated above.
  • the compounds of formula II wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl are prepared by reacting the compound of formula III with a compound of the formula R 2 --CH 2 --CO 2 R 1 , wherein R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 , respectively, in the presence of a base.
  • the reaction is, generally, effected in an aprotic polar solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO) or N-methylpyrrolidone at a temperature from about 25° to about 100° C.
  • Suitable bases include alkali metal hydroxides and hydrides and hindered (C 1 -C 6 )alkoxides such as KOH, NaOH, NaH and potassium-t-butoxide.
  • the compound of formula II wherein R 2 and R 1 are each hydrogen is prepared by heating a compound of formula II wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl with an acid.
  • the conditions and compositions for use in this process are as indicated above.
  • the compound of formula II wherein R 2 is hydrogen and R 1 is (C 1 -C 6 )alkyl is prepared by treating the compound of the formula II wherein R 2 and R 1 are each hydrogen with a (C 1 -C 6 )alkanol in the presence of an acidic esterification catalyst.
  • Suitable esterification catalysts include sulfuric acid, p-toluenesulfonic acid, trifluoromethanesulfonic and thionyl chloride. The reaction is generally carried out at a temperature from about 25° to about 110° C.
  • a solvent such as a (C 1 -C 6 )alkanol neat or diluted with a halogenated hydrocarbon or an aromatic hydrocarbon such as CH 2 Cl 2 , CHCl 2 , CHCl 3 and toluene.
  • the compound of formula III is prepared by reducing the compound of formula IV.
  • Suitable reducing agents include sodium triacetoxyborohydride and sodium cyanoborohydride.
  • the reaction is effected in the presence of a (C 1 -C 6 )alkanoic acid such as acetic acid.
  • Suitable solvents for use in this process include halogenated hydrocarbons such as CH 2 Cl 2 and 1,2-dichloroethane and aprotic polar solvents such as THF, DMF and DMSO.
  • the reaction may be carried out at a temperature from about 0° to about 75° C.
  • the compound of formula IV is prepared by reacting the compound of the formula V with the compound of the formula ##STR30## in the presence of a (C 1 -C 6 )alkanoic acid such as acetic acid.
  • the reaction is usually carried out in solvents which include acetic acid, DMF, DMSO and THF at temperatures from about 20° to about 100° C.
  • the compound of formula V is prepared by treating the compound of the formula VI with an enamine forming compound either neat or in inert solvents such as aprotic polar solvents.
  • Enamine forming compounds include t-butoxybis(dimethylamino)methane and dimethylformamide dialkylacetals.
  • Preferred enamine compounds are t-butoxy-bis(dimethylamino)methane and dimethylformamide dimethylacetal.
  • Solvents for use in this reaction include THF, DMF and the neat reagent.
  • Preferred conditions are those wherein the enamine forming compounds are t-butoxy-bis(dimethylamino)methane and dimethylformamide dimethylacetal and the solvents are THF and DMF, respectively.
  • the compound of formula II wherein R 2 is hydrogen and R 1 is (C 1 -C 6 )alkyl may, alternatively, be prepared by reacting a compound of the formula VII, wherein R 1 and R 2 are as defined above, with the compound of the formula ##STR31## in the presence of a base.
  • Suitable bases for use in this aspect of the invention include trialkylamines and cycloheteroarylamines such as triethylamine, pyridine and N-methylmorpholine.
  • the reaction is usually carried out in inert solvents which include aprotic polar solvents such as THF, DMF and DMSO and halogenated hydrocarbons such as CH 2 Cl 2 at temperatures from about 0° to about 50° C.
  • the compound of formula VII is prepared by reacting a compound of formula VIII wherein R 2 is CN or CO 2 R 1 and R 1 is (C 1 -C 6 )alkyl with an acid at a temperature from about 50° to about 110° C.
  • Suitable acids include concentrated hydrochloric acid and sulfuric acid.
  • Solvents which may be used for this reaction include the acid reagent, e.g., the concentrated hydrochloric or sulfuric acid, which can be diluted with a (C 1 -C 4 )alkanoic acid.
  • the compound of formula VIII may be prepared by reacting the compound of formula IX with a compound of the formula R 2 --CH 2 --CO 2 R 1 , wherein R 1 is (C 1 -C 6 )alkyl and R 2 is CN or CO 2 R 1 , in the presence of a base.
  • Suitable bases include alkali metal hydrides, hydroxides and hindered (C 1 -C 6 )alkoxides, such as KOH, NaH and potassium t-butoxide.
  • the reaction is generally effected in a solvent such as DMF, DMSO or N-methylpyrrolidine at a temperature from about 25° to about 75° C.
  • the compound of formula IX is prepared by reacting the compound of the formula X with the compound of formula ##STR32## in the presence of (CH 3 CO 2 ) 3 NaBH and acetic acid.
  • Solvents useful in this aspect of the invention include halogenated hydrocarbons and such as methylene chloride and 1,2-dichloroethane and aprotic polar solvents such as THF, DMF and DMSO.
  • the compound of formula X is prepared by reacting the compound of formula V with a mild organic or mineral acid solution such as acetic or oxalic acid or dilute (0.5-1N) hydrochloric or sulfuric acid, in appropriate solvents such as water, halogenated hydrocarbons and hexanes, at a temperature from about 0° to about 50° C.
  • a mild organic or mineral acid solution such as acetic or oxalic acid or dilute (0.5-1N) hydrochloric or sulfuric acid, in appropriate solvents such as water, halogenated hydrocarbons and hexanes, at a temperature from about 0° to about 50° C.
  • the neuroleptic activity of the compound of formula I may be demonstrated by methods based on standard procedures.
  • adult male Sprague-Dawley rats are pretreated with appropriate doses of the test compound by subcutaneous injection.
  • One half hour later, all rats are injected intraperitoneally with 1 mg/kg apomorphine hydrochloride dissolved in an 0.1% ascorbate solution and their behavior evaluated.
  • the neuroleptic activity of the compound of formula I makes it useful for treating psychotic disorders in human subjects.
  • the compound is useful for treating psychotic disorders of the schizophrenic types, and in particular the compound is useful for removing or ameliorating such symptoms as anxiety, agitation, excessive aggression, tension, and social or emotional withdrawal in psychotic patients.
  • the compound of formula I, or a pharmaceutically-acceptable salt thereof can be administered to a human subject either alone or, preferably, in combination with pharmaceutically-acceptable carriers or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice.
  • the compound can be administered orally or parenterally.
  • Parenteral administration includes, especially, intravenous and intramuscular administration.
  • the weight ratio of active ingredient to carrier will normally be in the range from 1:6 to 2:1, and preferably 1:4 to 1:1. However, in any given case, the ratio chosen will depend on such factors as the solubility of the active component, the dosage contemplated and the precise route of administration.
  • the compound of formula I can be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
  • sterile solutions of the active ingredient can be prepared, and the pH of the solutions should be suitably adjusted and buffered.
  • the total concentration of solutes should be controlled to render the preparation isotonic.
  • the daily dosage will normally be determined by the prescribing physician. Moreover, the dosage will vary according to the age, weight and response of the individual patient as well as the severity of the patient's symptoms. However, in most instances, an effective amount for treating a psychotic disorder will be a daily dosage in the range from 5 to 500 mg, and preferably 50 to 100 mg, in single or divided doses, orally or parenterally.
  • the title compound (2.4 g, 50 mmol) from the previous example was dissolved in a mixture of tetrahydrofuran (24 ml) and ethanol (24 ml). Water (16 ml) was added to the stirred solution followed by sodium hydrosulfite (2.03 g, 116 mmol) and the mixture was heated to reflux. After 10 minutes, the solids had dissolved and a second portion of sodium hydrosulfite (1.3 g, 76 mmol) and water were added. The reaction mixture was heated on a steam bath for 4 hours. The reaction mixture was cooled, 6N hydrochloric acid (8.4 ml) was added and the reaction mixture was again heated for 15 minutes on the steam bath.
  • the aqueous layer was adjusted to pH 6 with 2N hydrochloric acid and the layers were separated.
  • the aqueous layer was extracted with ethyl acetate.
  • the combined organic layers were washed with water and brine, dried and filtered.
  • the ethyl acetate solution was concentrated to 20 ml and p-toluenesulfonic acid (0.44 g, 2.3 mmol) was added with stirring.
  • the tosylate salt of the desired product was collected and dried in vacuo. The yield was 1.27 g, 82.5%. mp 204°- 7° C. Analysis calculated for C 30 H 30 N 5 O 7 Cl 2 S: C, 53.61; H, 4.50; N, 10.42. Found: C, 53.52; H, 4.15; N, 10.70.
  • the tosylate salt was dissolved in water and adjusted to a pH of 12 with 1N sodium hydroxide. The basic solution was extracted with ethyl acetate. The ethyl acetate was evaporated to yield the free base as a purple solid, mp 91°-100° C.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

A process for preparing the compound of the formula ##STR1## which comprises treating a compound of the formula ##STR2## wherein R2 is hydrogen, CN or CO2 R1 and R1 is hydrogen or (C1 -C6)alkyl with a reducing agent with the proviso that when R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl the product of the reduction is heated with an acid. Compounds of formula II wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl or R2 is hydrogen and R1 is (C1 -C6)alkyl or hydrogen. The compound of formula VII R1 is (C1 -C6)alkyl. The compound of formula III. The compound of formula I is useful in the treatment of psychotic disorders.

Description

BACKGROUND OF THE INVENTION
This invention relates to processes and intermediates for the its preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one is useful in the treatment of psychotic disorders.
5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one and a process for its preparation are disclosed in U.S. Pat. No. 4,831,031.
SUMMARY OF THE INVENTION
The present invention provides a process for preparing the compound of the formula ##STR3## which comprises treating a compound of the formula ##STR4## wherein R2 is hydrogen, CN or CO2 R1 and R1 is hydrogen or (C1 -C6)alkyl with a reducing agent with the proviso that when R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl the product of the reduction is heated with an acid.
The invention also provides a process for preparing a compound of the formula II
a) wherein R2 and R1 are both hydrogen by heating the compound of the formula II wherein R1 is (C1 -C6)alkyl and R2 is CN or CO2 R1 in the presence of an aqueous acid:
b) wherein R2 is hydrogen and R1 is (C1 -C6)alkyl by
i) treating a compound of the formula ##STR5## wherein R1 is (C1 -C6)alkyl with the compound of the formula ##STR6## in the presence of a base; or ii) treating a compound of the formula II wherein R1 and R2 are both hydrogen with a (C1 -C6)alkanol in the presence of an acidic esterification catalyst; or
c) wherein R1 is (C1 -C6)alkyl and R2 is CN or CO2 R1 by treating the compound of the formula ##STR7## with a compound of the formula R2 --CH2 --CO2 R1, wherein R2 is CN or CO2 R1, respectively, and R1 is (C1 -C6)alkyl in the presence of a base.
In another aspect the invention provides a process for preparing the compound of the formula III by treating the compound of the formula ##STR8## with a reducing agent.
According to another aspect of the invention there is provided a process for preparing the compound of formula IV which comprises treating the compound of the formula ##STR9## with the compound of the formula ##STR10## in the presence of a (C1 -C6) alkanoic acid.
Another aspect of the invention provides a process for preparing the compound of the formula V which comprises treating a compound of the formula ##STR11## with an enamine forming compound selected from the group consisting of t-butoxybis(dimethylamino)methane and dimethylformamide dialkylacetals in an inert solvent.
Yet another aspect of the invention provides a process for preparing a compound of the formula VII by treating a compound of the formula ##STR12## wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl with an acid at an elevated temperature.
In accordance with another aspect of the invention there is provided a process for preparing a compound of the formula VIII which comprises treating the compound of the formula ##STR13## with a compound of the formula R2 --CH2 --CO2 R1 wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl in the presence of a base.
Another aspect of the invention provides a process for preparing the compound of the formula IX which comprises treating the compound of the formula ##STR14## with the compound of the formula ##STR15## in the presence of (CH3 CO2)3 NaBH and acetic acid.
According to another aspect of the invention there is provided a process for preparing a compound of the formula X by treating the compound of formula V with oxalic acid.
Another aspect of the invention provides a process for preparing the compound of the formula ##STR16## which comprises the steps of
I. treating a compound of the formula ##STR17## a. 1) with the compound of the formula ##STR18## in the presence of a (C1 -C6) alkanoic acid to form the compound of the formula ##STR19##
2) treating the compound of formula IV with a reducing agent to form the compound of the formula ##STR20##
3) treating the compound of formula III with a compound of the formula R2 --CH2 --CO2 R1 wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl to form a compound of formula ##STR21## wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl;
4) treating the product of step 3) with an acid at an elevated temperature to form a the compound of formula II wherein R2 and R1 are both hydrogen; and
5) treating the product of step 4 with a (C1 -C6)alkanol in the presence of an acidic esterification catalyst to form the compound of formula II wherein R2 is hydrogen and R1 is (C1 -C6)alkyl; or
b) 1) treating the compound of formula V with a weak acid to form the compound of formula ##STR22##
2) treating the compound of formula X with the compound of the formula ##STR23## in the presence of (CH3 CO2)3 NaBH and acetic acid to form the compound of formula ##STR24##
3) treating the compound of formula IX with a compound of the formula R2 --CH2 --CO2 R1 wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl to form a compound of formula ##STR25## wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl;
4) treating the compound of formula VIII with an acid at an elevated temperature to form the compound of formula ##STR26## wherein R1 is (C1 -C6)alkyl; and
5) treating the compound of formula VII with the compound of formula ##STR27## in the presence of a base to form the compound of formula II wherein R2 is hydrogen and R1 is (C1 -C6)alkyl; and II. treating a compound of the formula ##STR28## wherein R2 is hydrogen, CN or CO2 R1 and R1 is hydrogen or (C1 -C6)alkyl with a reducing agent with the proviso that when R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl the product of the reduction is heated with an acid.
Compounds of the formulae II and III wherein R1 and R2 are as defined above are novel and additional features of the invention.
DETAILED DESCRIPTION OF THE INVENTION
The processes of the instant invention are illustrated in schemes 1 and 2. ##STR29##
As shown in Scheme 1 a compound of the formula II wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl is treated with a reducing agent and the resulting product is heated with an acid to prepare compound of formula I. Generally the reaction is carried out in a reaction inert solvent. Suitable reducing agents are sodium hydrosulfite, hydrogen in the presence of a hydrogenation catalyst, iron in acetic acid, zinc and CaCl2 in acetic acid and NaH2 PO2 in the presence of Pd/C. A preferred reducing agent is sodium hydrosulfite. The temperature of the reduction stage is from about 10° to about 100° C. When sodium hydrosulfite is the reducing agent the reaction temperature is preferably from about 65° to about 80° C. The temperature at the acid treatment stage is from about 50° to about 110° C. Acids which are useful in this stage are strong mineral acids such as concentrated hydrochloric and 6N sulfuric acids. Suitable solvents are water and water miscible solvents such as (C1 -C6)alkanols, tetrahydrofuran (THF) and dioxane and mixtures thereof.
Alternatively, a compound of formula II wherein R2 is hydrogen and R1 is hydrogen or (C1 -C6)alkyl is converted to the compound of formula I by treatment with a reducing agent. Suitable conditions for the reduction are indicated above.
The compounds of formula II wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl are prepared by reacting the compound of formula III with a compound of the formula R2 --CH2 --CO2 R1, wherein R1 is (C1 -C6)alkyl and R2 is CN or CO2 R1, respectively, in the presence of a base. The reaction is, generally, effected in an aprotic polar solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO) or N-methylpyrrolidone at a temperature from about 25° to about 100° C. Suitable bases include alkali metal hydroxides and hydrides and hindered (C1 -C6)alkoxides such as KOH, NaOH, NaH and potassium-t-butoxide.
The compound of formula II wherein R2 and R1 are each hydrogen is prepared by heating a compound of formula II wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl with an acid. The conditions and compositions for use in this process are as indicated above.
The compound of formula II wherein R2 is hydrogen and R1 is (C1 -C6)alkyl is prepared by treating the compound of the formula II wherein R2 and R1 are each hydrogen with a (C1 -C6)alkanol in the presence of an acidic esterification catalyst. Suitable esterification catalysts include sulfuric acid, p-toluenesulfonic acid, trifluoromethanesulfonic and thionyl chloride. The reaction is generally carried out at a temperature from about 25° to about 110° C. in a solvent such as a (C1 -C6)alkanol neat or diluted with a halogenated hydrocarbon or an aromatic hydrocarbon such as CH2 Cl2, CHCl2, CHCl3 and toluene.
The compound of formula III is prepared by reducing the compound of formula IV. Suitable reducing agents include sodium triacetoxyborohydride and sodium cyanoborohydride. The reaction is effected in the presence of a (C1 -C6)alkanoic acid such as acetic acid. Suitable solvents for use in this process include halogenated hydrocarbons such as CH2 Cl2 and 1,2-dichloroethane and aprotic polar solvents such as THF, DMF and DMSO. The reaction may be carried out at a temperature from about 0° to about 75° C.
The compound of formula IV is prepared by reacting the compound of the formula V with the compound of the formula ##STR30## in the presence of a (C1 -C6)alkanoic acid such as acetic acid. The reaction is usually carried out in solvents which include acetic acid, DMF, DMSO and THF at temperatures from about 20° to about 100° C.
The compound of formula V is prepared by treating the compound of the formula VI with an enamine forming compound either neat or in inert solvents such as aprotic polar solvents. Enamine forming compounds include t-butoxybis(dimethylamino)methane and dimethylformamide dialkylacetals. Preferred enamine compounds are t-butoxy-bis(dimethylamino)methane and dimethylformamide dimethylacetal. Solvents for use in this reaction include THF, DMF and the neat reagent. Preferred conditions are those wherein the enamine forming compounds are t-butoxy-bis(dimethylamino)methane and dimethylformamide dimethylacetal and the solvents are THF and DMF, respectively.
As shown in Scheme 2 the compound of formula II wherein R2 is hydrogen and R1 is (C1 -C6)alkyl may, alternatively, be prepared by reacting a compound of the formula VII, wherein R1 and R2 are as defined above, with the compound of the formula ##STR31## in the presence of a base. Suitable bases for use in this aspect of the invention include trialkylamines and cycloheteroarylamines such as triethylamine, pyridine and N-methylmorpholine. The reaction is usually carried out in inert solvents which include aprotic polar solvents such as THF, DMF and DMSO and halogenated hydrocarbons such as CH2 Cl2 at temperatures from about 0° to about 50° C.
The compound of formula VII is prepared by reacting a compound of formula VIII wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl with an acid at a temperature from about 50° to about 110° C. Suitable acids include concentrated hydrochloric acid and sulfuric acid. Solvents which may be used for this reaction include the acid reagent, e.g., the concentrated hydrochloric or sulfuric acid, which can be diluted with a (C1 -C4)alkanoic acid.
The compound of formula VIII may be prepared by reacting the compound of formula IX with a compound of the formula R2 --CH2 --CO2 R1, wherein R1 is (C1 -C6)alkyl and R2 is CN or CO2 R1, in the presence of a base. Suitable bases include alkali metal hydrides, hydroxides and hindered (C1 -C6)alkoxides, such as KOH, NaH and potassium t-butoxide. The reaction is generally effected in a solvent such as DMF, DMSO or N-methylpyrrolidine at a temperature from about 25° to about 75° C.
The compound of formula IX is prepared by reacting the compound of the formula X with the compound of formula ##STR32## in the presence of (CH3 CO2)3 NaBH and acetic acid. Solvents useful in this aspect of the invention include halogenated hydrocarbons and such as methylene chloride and 1,2-dichloroethane and aprotic polar solvents such as THF, DMF and DMSO.
The compound of formula X is prepared by reacting the compound of formula V with a mild organic or mineral acid solution such as acetic or oxalic acid or dilute (0.5-1N) hydrochloric or sulfuric acid, in appropriate solvents such as water, halogenated hydrocarbons and hexanes, at a temperature from about 0° to about 50° C.
The neuroleptic activity of the compound of formula I may be demonstrated by methods based on standard procedures. In one method, adult male Sprague-Dawley rats are pretreated with appropriate doses of the test compound by subcutaneous injection. One half hour later, all rats are injected intraperitoneally with 1 mg/kg apomorphine hydrochloride dissolved in an 0.1% ascorbate solution and their behavior evaluated.
The neuroleptic activity of the compound of formula I makes it useful for treating psychotic disorders in human subjects. For example, the compound is useful for treating psychotic disorders of the schizophrenic types, and in particular the compound is useful for removing or ameliorating such symptoms as anxiety, agitation, excessive aggression, tension, and social or emotional withdrawal in psychotic patients.
The compound of formula I, or a pharmaceutically-acceptable salt thereof, can be administered to a human subject either alone or, preferably, in combination with pharmaceutically-acceptable carriers or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. The compound can be administered orally or parenterally. Parenteral administration includes, especially, intravenous and intramuscular administration. Additionally, in a pharmaceutical composition comprising the compound of formula I, or a pharmaceutically-acceptable salt thereof, the weight ratio of active ingredient to carrier will normally be in the range from 1:6 to 2:1, and preferably 1:4 to 1:1. However, in any given case, the ratio chosen will depend on such factors as the solubility of the active component, the dosage contemplated and the precise route of administration.
For oral use the compound of formula I can be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. For intramuscular and intravenous use, sterile solutions of the active ingredient can be prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic.
When the neuroleptic agent of formula I is to be used in a human subject to treat a psychotic disorder, the daily dosage will normally be determined by the prescribing physician. Moreover, the dosage will vary according to the age, weight and response of the individual patient as well as the severity of the patient's symptoms. However, in most instances, an effective amount for treating a psychotic disorder will be a daily dosage in the range from 5 to 500 mg, and preferably 50 to 100 mg, in single or divided doses, orally or parenterally.
The following examples are provided solely for the purpose of further illustration.
EXAMPLE 1 2,5-Dichloro-4-methyl-nitrobenzene
Prepared by a modification of the method of H. D. Dakin and J. B. Cohen, J. Chem. Soc., 79, 1130 (1901). 2,5-Dichlorotoluene (18.7 g, 0.116 mol) was added in one portion to a 10° C. mixture of concentrated sulfuric acid (24 ml) and glacial acetic acid (10 ml). This was stirred at about 10° C. while a cold mixture of 70% nitric acid (8.2 ml) and concentrated sulfuric acid (8.2 ml) was added dropwise over 10 min. The reaction mixture was warmed slowly to room temperature and stirred for 2 hours. The reaction mixture was then recooled to 10° C. with an ice bath and quenched with ice and methylene chloride. The layers were separated and the aqueous layer extracted with methylene chloride. The combined organic layers were washed two times with water, two times with saturated sodium bicarbonate solution and one time with brine. After drying over magnesium sulfate, the solvent was evaporated in vacuo and the crude product crystallized from isopropanol (30 ml). The yield of light yellow solid was 13.4 g, 56%; NMR (CDCl3) δ 7.91 (s, 1), 7.42 (s, 1), 2.43 (s, 3).
EXAMPLE 2 2,5-Dichloro-4-(2-dimethylaminoethenyl)-nitrobenzene
2,5-Dichloro-4-methyl-nitrobenzene (50 g, 0.24 mol) was heated at reflux, in tetrahydrofuran (200 ml), with t-butoxy-bis(dimethylamino)methane (63.3 g, 0.364 mol) for 8 hours. The reaction mixture was cooled to room temperature and slowly poured into hexanes (3L) with stirring. The desired product was collected by filtration as a dark red solid, 36.9 g, 58% yield. mp 173°-5° C. NMR (CDCl3) δ 8.01 (s, 1), 7.32 (s, 1), 7.08 (d, 1), 5.27 (d, 1), 3.00 (s, 6). Analysis Calculated for C10 H10 N2 O2 Cl2 : C, 45.99; H, 3.86; N, 10.73, Found: C, 45.91; H, 3.72; N, 10.61.
EXAMPLE 3 2,5-Dichloro-4-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethenyl)-nitrobenzene
2,5-Dichloro-4-(2-dimethylaminoethenyl)-nitrobenzene (15 g, 0.057 mol) and 4-(1,2-benzisothiazol-3-yl)-piperazine (18.9 g, 0.086 mol) were combined in acetic acid (150 ml) and stirred overnight at room temperature under a nitrogen atmosphere. The slurry was poured slowly into a mixture of hexanes (300 ml) and isopropanol (300 ml) with stirring. The product was isolated by filtration as a brick red solid and washed with hexanes. The yield was 23.4 g, 93%; mp 194°-5° C. NMR (CDCl3) δ 8.05 (s, 1), 7.95-7.80 (m, 2), 7.56-7.35 (m, 3), 7.01 (d, 1), 5.60 (d, 1), 3.95-3.46 (m, 8). Analysis Calculated for C19 H16 N4 O2 Cl2 S: C, 52.41; H, 3.70; N, 12.87. Found: C, 52.05; H, 3.36; N, 12.58.
EXAMPLE 4 2,5-Dichloro-4-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-nitrobenzene
The enamine from the preceding example (22.5 g, 0.052 mol) was suspended in 1,2-dichloroethane (340 ml) with acetic acid (17.8 ml) and stirred under a nitrogen atmosphere while sodium triacetoxyborohydride (21.9 g, 0.1 mol) was added in portions as a solid. The reaction was stirred overnight. Aqueous sodium carbonate solution was then added to the reaction mixture and then ethyl acetate (300 ml). The layers were separated and the aqueous layer extracted a second time with ethyl acetate. The combined organic layers were washed with water and brine and dried over magnesium sulfate. The crude product was isolated from the organic solution and purified by recrystallization from acetonitrile; 16.14 g, 71% yield. mp 153°-7° C. NMR (CDCl3) δ 7.97 (s, 1), 7.91 (d, 1), 7.82 (d, 1), 7.50 (s, 1), 7.48 (dd,1), 7.37 (dd, 1), 3.58 (m, 4), 3.00 (t, 2), 2.78 (m, 4), 2.72 (t, 2). Analysis Calculated for C19 H18 N4 O2 Cl2 S: C, 52.18; H, 4.15; N, 12.81. Found: C, 51.97; H, 3.98; N, 12.65. The structure was confirmed by single crystal x-ray analysis.
EXAMPLE 5 5-Chloro-4-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-2-(bis-(methoxycarbonyl)methyl)-nitrobenzene
2,5-Dichloro-4-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-nitrobenzene (2.4 g, 55 mmol) and dimethylmalonate (1.81 g, 137 mmol) were dissolved in N-methyl-pyrrolidine (24 ml) and a stream of nitrogen was bubbled through the solution for 15 minutes to remove any oxygen. Powdered potassium hydroxide (0.77 g, 137 mmol) was added in one portion and the mixture heated at 40°-5° C. for 5 hours. The reaction mixture was cooled and diluted with ethyl acetate and washed with saturated ammonium chloride solution, water, and brine. The organic layer was dried over magnesium sulfate, filtered and evaporated to afford the crude product. The pure product was isolated by flash chromatography over silica gel with ethyl acetate/hexanes (4:6) as a light yellow solid, 1.32 g, 45% yield. mp 128°-31° C. NMR (CDCl3) δ 8.10 (s, 1), 7.90 (d, 1), 7.81 (d, 1), 7.48 (t and s, 2), 7.37 (t, 1), 5.33 (s, 1), 3.82 (s, 6), 3.58 (m, 4), 3.06 (t, 2), 2.80-2.70 (m, 6). The structure was confirmed by single crystal x-ray analysis.
EXAMPLE 6 5-(2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl)-4-chloro-2-nitrophenyl acetic acid
The 2-nitrophenyl-malonate (4.4 g, 83 mmol) from the previous example was refluxed in 3N hydrochloric acid (90 ml) for 20 hours. The reaction mixture was cooled and the precipitated product isolated by filtration and dried in vacuo; 4 g, 95%.mp 209°-212° C. (dec). NMR (DMSO-d6) δ 8.21 (s, 1), 8.15 (d, 1), 8.0 (d,1), 7.67 (s, 1), 7.59 (t, 1), 7.48 (t, 1), 4.10 (br d, 2), 4.00 (s, 2), 3.79-3.23 (m, 8).
EXAMPLE 7 Methyl 5-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-4-chloro-2-nitrophenyl acetate
Methanol (62 ml) was stirred at -10° C. under a nitrogen atmosphere. Thionyl chloride (1 ml, 135 mmol) was added slowly, dropwise, to the methanol and then the product from the previous reaction was added in one portion as a solid. The cooling was removed and the reaction heated to reflux for 3 hours. The reaction mixture was evaporated in vacuo to remove the methanol and then partitioned between ethyl acetate and aqueous sodium carbonate. The aqueous layer was extracted a second time with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate and evaporated to give the desired amino acid ester as an oil; 3 g, 94% yield. NMR (CDCl3) δ 8.18 (s, 1), 7.90 (d, 1), 7.81 (d, 1), 7.48 (t, 1), 7.36 (t, 1), 7.31 (s, 1), 4.00 (s, 2), 3.72 (s, 3), 3.63 (m, 4), 3.09 (m, 2), 2.89-2.72 (m, 6).
EXAMPLE 8 6-Chloro-5-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-oxindole
The title compound (2.4 g, 50 mmol) from the previous example was dissolved in a mixture of tetrahydrofuran (24 ml) and ethanol (24 ml). Water (16 ml) was added to the stirred solution followed by sodium hydrosulfite (2.03 g, 116 mmol) and the mixture was heated to reflux. After 10 minutes, the solids had dissolved and a second portion of sodium hydrosulfite (1.3 g, 76 mmol) and water were added. The reaction mixture was heated on a steam bath for 4 hours. The reaction mixture was cooled, 6N hydrochloric acid (8.4 ml) was added and the reaction mixture was again heated for 15 minutes on the steam bath. The reaction mixture was made basic with sodium carbonate and the crude product collected by filtration and recrystallized from tetrahydrofuran, 0.8 g, 40% yield. NMR (DMSO-d6) δ 8.05 (d, 2), 7.55 (t, 1), 7.42 (t, 1), 7.21 (s, 1), 6.80 (s, 1), 3.45 (s, 2), 2.83 (m, 2), 2.70 (m, 4), 2.54 (m, 6). This was identical with product prepared previously.
EXAMPLE 9 Methyl [5-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-4-chloro-2-nitrophenyl]-cyanoacetate
2,5-Dichloro-4-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-nitrobenzene (1 g, 2.3 mmol) and methyl cyanoacetate (0.44 ml, 5 mmol) were dissolved in N-methylpyrrolidine (25 ml) under nitrogen. Powdered potassium hydroxide (0.28 g, 5 mmol) was added and the mixture was heated to 57° C. for 4 hours at which time tic showed that the starting material had reacted. The cooled reaction mixture was poured into a stirred mixture of saturated aqueous ammonium chloride and ethyl acetate. The aqueous layer was adjusted to pH 6 with 2N hydrochloric acid and the layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried and filtered. The ethyl acetate solution was concentrated to 20 ml and p-toluenesulfonic acid (0.44 g, 2.3 mmol) was added with stirring. The tosylate salt of the desired product was collected and dried in vacuo. The yield was 1.27 g, 82.5%. mp 204°- 7° C. Analysis calculated for C30 H30 N5 O7 Cl2 S: C, 53.61; H, 4.50; N, 10.42. Found: C, 53.52; H, 4.15; N, 10.70.
The tosylate salt was dissolved in water and adjusted to a pH of 12 with 1N sodium hydroxide. The basic solution was extracted with ethyl acetate. The ethyl acetate was evaporated to yield the free base as a purple solid, mp 91°-100° C. NMR (CDCl3) δ 8.27 (s, 1), 7.91 (d, 1), 7.82 (d, 1), 7.78 (s, 1), 7.49 (t, 1), 7.38 (t, 1), 5.68 (s, 1), 3.88 (m, 4), 3.1 (m, 2,), 2.8, (m, 6).
Hydrolysis of the tosylate salt or free base in concentrated hydrochloric acid at 100° C. provided a product identical with that from Example 6.
EXAMPLE 10 2,5-Dichloro-4-nitrophenylacetaldehyde
2,5-Dichloro-4-(2-dimethylaminoethenyl)-nitrobenzene (10 g, 38.3 mmol) was dissolved in methylene chloride (200 ml) and stirred with a solution of oxalic acid (14.5 g, 115 mmol) in water (80 ml) at room temperature for 18 hours. The layers were separated and the aqueous layer extracted with methylene chloride (50 ml). The combined organic layers were washed with water and brine, dried over magnesium sulfate and filtered. The solution was evaporated to yield the title compound. NMR (CDCl3) δ 9.70 (s, 1), 8.01 (s, 1), 7.49 (s, 1), 3.98 (s, 2).
EXAMPLE 11 2,5-Dichloro-4-(2-[4-(t-butoxycarbonyl)-1-piperazinyl]ethyl)-nitrobenzene
A methylene chloride solution of the title compound of Example 10 was stirred at room temperature under nitrogen. Acetic acid (8.8 ml, 153 mmol) was added in one portion followed by t-butylpiperazinecarboxylate (8.4 g, 50 mmol). Sodium triacetoxy-borohydride (16.2 g, 77 mmol) was added in portions as a solid and the reaction mixture stirred at room temperature for three hours. The reaction mixture was washed two times with excess saturated sodium carbonate solution and one time each with water and brine. The organic layer was dried over magnesium sulfate, filtered and evaporated to afford the title product as an oil 15.6 g, (98% crude yield). This was suitable for use in the next reaction without further purification. NMR (CDCl3) δ 7.92 (s, 1), 7.48 (s, 1), 3.43 (m, 4), 2.97 (t, 2), 2.62 (t, 2), 2.49 (m, 4), 1.43 (s, 9).
EXAMPLE 12 5-Chloro-4 -(2-[4-(t-butoxycarbonyl)-1-piperazinyl]ethyl)-2-(bis-(methoxycarbonyl)methyl)-nitrobenzene
2,5-Dichloro-4-(2-[4-(t-butoxycarbonyl)-1-piperazinyl]ethyl)-nitrobenzene (5 g, 13 mmol) and dimethyl malonate (3.8 ml, 33 mmol) were stirred in N-methyl pyrrolidone (75 ml), at room temperature under nitrogen, while sodium hydride (1.33 g, 33 mmol, 60% in oil) was added. The reaction mixture was heated to 57° C. for 7 hours. The reaction mixture was cooled and poured into saturated aqueous ammonium chloride solution and extracted twice with ethyl acetate. The combined organic layers were washed with water three times, one time with brine and dried over magnesium sulfate. Evaporation of the solvent in vacuo gave an oil which was chromatographed over flash silica gel with ethyl acetate/hexanes followed by ethyl acetate. The fractions containing the desired product were combined and evaporated to give an oil, 2.5 g, 48% yield. NMR (CDCl3) δ 8.09 (s, 1), 7.45 (s, 1), 5.31 (s, 1), 3.79 (s, 6), 3.43 (m, 4), 2.98 (t, 2), 2.61 (t, 2), 2.47 (m, 4), 1.43 (s, 9).
EXAMPLE 13 Methyl 5-(2-(1-piperazinyl)ethyl)-4-chloro-2-nitrophenyl acetate
5-Chloro-4-(2-[4-(t-butoxycarbonyl)-1-piperazinyl]ethyl)-2-(bis-(methoxycarbonyl)methyl)-nitrobenzene (2.5 g, 6.3 mmol) was refluxed for 5 hours in 6N hydrochloric acid. The reaction mixture was then stirred at room temperature overnight and evaporated in vacuo to a solid which was slurried in isopropanol and collected; NMR (D2 O) δ 8.25 (s, 1), 7.40 (s, 1), 4.03 (s, 2), 3.8-3.25 (4 multiplets for piperazine and ethyl groups). The amino acid hydrochloride was dissolved in methanol (20 ml) and cooled in an ice bath while thionyl chloride (1 ml, 14 mmol) was added dropwise. The solution was heated at reflux for 2 hours then cooled and evaporated in vacuo to a foam. The crude product was partioned between ethyl acetate and water at pH 12. The organic layer was dried over sodium sulfate, filtered and evaporated to afford the desired ester as a dark oil, 1.34 g, 67% yield. NMR (CDCl3) δ 8.12 (s, 1), 7.22 (s, 1), 3.94 (s, 2), 3.71 (s, 3), 2.96 and 2.89 (m, 6), 2.58 and 2.49 (m, 6).
EXAMPLE 14 Methyl 5-(2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl)-4-chloro-2-nitrophenyl acetate
Methyl 5-(2-(1-piperazinyl)ethyl)-4-chloro-2-nitrophenyl acetate (175 mg, 0.5 mmol) and 3-(trifluoromethylsulfonyloxy)-1,2-benzisothiazole (163 mg, 0.58 mmol) [prepared from 2,1-benzisothiazol-3(1H)-one with trifluoro-methanesulfonyl anhydride and pyridine in methylene chloride] were stirred in dry tetrahydrofuran (2.5 ml) with triethylamine (0.11 ml, 0.8 mmol) for 20 hours at room temperature. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium carbonate, water and brine. The organic layer was dried over magnesium sulfate, filtered, and evaporated in vacuo. The crude residue was chromatographed over flash silica gel with 10% ethyl acetate in chloroform to afford the desired product; 60 mg, 25% yield. This material was identical with that of Example 7.

Claims (17)

What is claimed is:
1. A process for preparing a compound of the formula ##STR33## which comprises treating a compound of the formula ##STR34## wherein R2 is hydrogen, CN or CO2 R1 and R1 is hydrogen or (C1 -C6)alkyl with a reducing agent selected from the group consisting of sodium hydrosulfite, hydrogen in the presence of a hydrogenation catalyst, iron in acetic acid, zinc and CaCl2 in acetic acid and NaH2 PO2 in the presence of Pd/C with the proviso that when R2 is CN or CO2 R1 and R1 is (C1 -C6) alkyl the product of the reduction is heated with an acid.
2. The process of claim 1 wherein said acid is selected from the group consisting of concentrated hydrochloric acid or concentrated hydrochloric acid diluted to 6N or 3N with water or acetic acid.
3. The process of claim 1 wherein said reduction is effect in an inert solvent selected from the group consisting of water, water miscible solvents and mixtures thereof.
4. The process of claim 1 wherein said reducing agent is sodium hydrosulfite and said solvent is THF.
5. The process of claim 1 wherein the compound of the formula II is prepared
a) when R2 and R1 are both hydrogen by heating the compound of the formula II wherein R1 is (C1 -C6)alkyl and R2 is CN or CO2 R1 in the presence of an aqueous acid:
b) when R2 is hydrogen and R1 is (C1 -C6)alkyl by
i) treating a compound of the formula ##STR35## wherein R1 is (C1 -C6)alkyl with the compound of the formula ##STR36## in the presence of a base; or ii) treating a compound of the formula II wherein R1 and R2 are both hydrogen with a (C1 -C6)alkanol in the presence of an acidic esterification catalyst; or
c) wherein R1 is (C1 -C6)alkyl and R2 is CN or CO2 R1 by treating the compound of the formula ##STR37## with a compound of the formula R2 --CH2 --CO2 R1, wherein R2 is CN or CO2 R1, respectively, and R1 is (C1 -C6)alkyl in the presence of a base.
6. The process of claim 5 wherein the compound of formula III is prepared by treating the compound of the formula ##STR38## with a reducing agent.
7. The process of claim 5 wherein the compound of formula VII is prepared by treating a compound of the formula ##STR39## wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl with an acid at an elevated temperature.
8. A process for preparing a compound of the formula ##STR40## which comprises the steps of I. treating a compound of the formula ##STR41## a) 1) with the compound of the formula ##STR42## in the presence of a (C1 -C6) alkanoic acid to form the compound of the formula ##STR43## 2) treating the compound of formula IV with a reducing agent to form the compound of the formula ##STR44## 3) treating the compound of formula III with a compound of the formula R2 --CH2 --CO2 R1 wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl in the presence of a base to form a compound of formula ##STR45## wherein R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl;
4) treating the product of step 3) with an acid at an elevated temperature to form the compound of formula II wherein R2 and R1 are both hydrogen; and
5) treating the product of step 4 with a (C1 -C6)alkanol in the presence of an acidic esterification catalyst to form the compound of formula II wherein R2 is hydrogen and R1 is (C1 -C6)alkyl; or
b) 1) treating the compound of formula V with a weak acid to form the compound of formula ##STR46## 2) treating the compound of formula X with the compound of formula ##STR47## in the presence of (CH3 CO2)3 NaBH and acetic acid to form the compound of formula ##STR48## 3) treating the compound of formula IX with a compound of the formula R2 --CH2 --CO2 R1 wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl in the presence of a base to form a compound of formula ##STR49## wherein R2 is CO2 R1 or CN and R1 is (C1 -C6)alkyl;
4) treating the compound of formula VIII with an acid at an elevated temperature to form the compound of formula ##STR50## wherein R1 is (C1 -C6)alkyl; and 5) treating the compound of formula VII with the compound of formula ##STR51## in the presence of a base to form the compound of formula II wherein R2 is hydrogen and R1 is (C1 -C6)alkyl; or
II. treating a compound of the formula ##STR52## wherein R2 is hydrogen, CN or CO2 R1 and R1 is hydrogen or (C1 -C6)alkyl with a reducing agent with the proviso that when R2 is CN or CO2 R1 and R1 is (C1 -C6)alkyl the product of the reduction is heated with an acid.
9. A compound of the formula ##STR53## wherein R1 is hydrogen or (C1 -C6)alkyl and R2 is hydrogen, CN or CO2 R1.
10. The compound of claim 9 wherein R1 is (C1 -C6)alkyl and R2 is CN or CO2 R1.
11. The compound of claim 10 wherein R1 is methyl.
12. The compound of claim 9 wherein R2 is hydrogen.
13. The compound of claim 12 wherein R1 is hydrogen.
14. The compound of claim 12 wherein R1 is CH3.
15. The compound of the formula ##STR54##
16. The compound of the formula ##STR55## wherein R1 is (C1 -C6)alkyl.
17. The compound of claim 16 wherein R1 is methyl.
US08/083,429 1993-06-28 1993-06-28 Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one Expired - Lifetime US5359068A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US08/083,429 US5359068A (en) 1993-06-28 1993-06-28 Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
AT94910016T ATE277041T1 (en) 1993-06-28 1994-04-06 PROCESS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF 5-(4-(BENZISOTHIAZOLE-3-YL)-PIPERAZINE-1-YL)ETHYL)-6 CHLORINE-1,3-DIHYDRO-INDOL-2-ONE
PT94910016T PT706524E (en) 1993-06-28 1994-04-06 PROCESSES AND INTERMEDIARIES FOR THE PREPARATION OF 5- [2- (4-BENZOISOTIAZOL-3-YL) PIPERAZIN-1-YL) ETHYL] -6-CHLORO-1,3-DIHYDRO-INDOL-2-ONA
EP94910016A EP0706524B1 (en) 1993-06-28 1994-04-06 Processes and intermediates for the preparation of 5- 2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK94910016T DK0706524T3 (en) 1993-06-28 1994-04-06 Methods and Intermediates for Preparation of 5- [2- (4- (Benzoisothiazol-3-yl) -piperazin-1-yl) ethyl] -6-chloro-1,3-dihydro-indol-2-one
ES94910016T ES2227524T3 (en) 1993-06-28 1994-04-06 INTERMEDIATE PROCEDURES AND COMPOUNDS FOR THE PREPARACOPM OF 5- (2- (4- (BENZOISOTIAZOL-3-IL) -PIPERAZIN-1-IL) ETIL) -6-CHLORINE-1,3-DIHYDRO-INDOL-2-ONA.
JP7502611A JP2667987B2 (en) 1993-06-28 1994-04-06 Method for producing 5- [2- (4- (benzoisothiazol-3-yl) -piperazin-1-yl) ethyl] -6-chloro-1,3-dihydro-indol-2-one and intermediate for production
CA002166203A CA2166203C (en) 1993-06-28 1994-04-06 Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]- 6-chloro-1,3-dihydro-indol-2-one
PCT/IB1994/000061 WO1995000510A1 (en) 1993-06-28 1994-04-06 Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DE69434020T DE69434020T2 (en) 1993-06-28 1994-04-06 METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF 5- [4- (BENZISOTHIAZOL-3-YL) -PIPERAZIN-1-YL) ETHYL] -6 CHLORO-1,3-DIHYDRO-INDOL-2-ONE
FI956279A FI119372B (en) 1993-06-28 1995-12-27 Processes and intermediates for the preparation of 5- [2- (4- (Benzo-isothiazol-3-yl) -piperazin-1-yl) -ethyl] -6-chloro-1,3-dihydro-indol-2-one

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/083,429 US5359068A (en) 1993-06-28 1993-06-28 Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Publications (1)

Publication Number Publication Date
US5359068A true US5359068A (en) 1994-10-25

Family

ID=22178273

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/083,429 Expired - Lifetime US5359068A (en) 1993-06-28 1993-06-28 Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Country Status (11)

Country Link
US (1) US5359068A (en)
EP (1) EP0706524B1 (en)
JP (1) JP2667987B2 (en)
AT (1) ATE277041T1 (en)
CA (1) CA2166203C (en)
DE (1) DE69434020T2 (en)
DK (1) DK0706524T3 (en)
ES (1) ES2227524T3 (en)
FI (1) FI119372B (en)
PT (1) PT706524E (en)
WO (1) WO1995000510A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0741129A2 (en) * 1995-04-24 1996-11-06 Sumitomo Seika Chemicals Co., Ltd. Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using it
US5935960A (en) * 1996-02-13 1999-08-10 Pfizer Inc. Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6245766B1 (en) * 1997-12-18 2001-06-12 Pfizer Inc Method of treating psychiatric conditions
WO2003070246A1 (en) * 2002-02-20 2003-08-28 Pfizer Products Inc. Controlled synthesis of ziprasidone and compositions thereof
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US20050059680A1 (en) * 2003-06-03 2005-03-17 Anna Balanov Crystalline ziprasidone HCI and processes for preparation thereof
US20050143397A1 (en) * 2003-10-24 2005-06-30 Gideon Pilarsky Processes for preparation of ziprasidone
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
US20060089502A1 (en) * 2004-10-27 2006-04-27 Sundaram Venkataraman Ziprasidone process
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
US20070078143A1 (en) * 2003-11-28 2007-04-05 Wockhardt Limited Method for preparing Ziprasidone monohydrochloride-hydrate
WO2008090048A2 (en) 2007-01-26 2008-07-31 Basf Se 3-amino-1,2-benzisothiazole compounds for combating animal pest ii

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126590A (en) * 1996-05-07 2001-11-25 Pfizer Mesylate trihydrates salt of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1-piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2(1h)-indol-2-one (=ziprasidone) and pharmaceutical compositions comprising it
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
WO2003099198A2 (en) * 2002-05-24 2003-12-04 Sun Pharmaceutical Industries Limited A process for the preparation of oxindole derivatives
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
JP4324221B2 (en) * 2005-08-26 2009-09-02 株式会社医薬分子設計研究所 Derivatives having PPAR agonist activity
PL391810A1 (en) 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna New ziprasidone salts and processes for the preparation thereof
CN104370850B (en) * 2013-08-14 2018-02-27 上海天慈生物谷生物工程有限公司 A kind of preparation method of Ziprasidone key intermediate
WO2023080193A1 (en) * 2021-11-04 2023-05-11 日産化学株式会社 Method for producing indole compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
US4690943A (en) * 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721712A (en) * 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4952584A (en) * 1986-01-11 1990-08-28 Beecham Group P.L.C. 9H-pyrido[2,B-8]indole-3-carboxylic acid ester compounds having useful pharmaceutical activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0252042A (en) * 1988-08-17 1990-02-21 Hitachi Plant Eng & Constr Co Ltd Air purifying agent and preparation thereof
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
US4721712A (en) * 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
US4690943A (en) * 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4952584A (en) * 1986-01-11 1990-08-28 Beecham Group P.L.C. 9H-pyrido[2,B-8]indole-3-carboxylic acid ester compounds having useful pharmaceutical activity
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Flitsch et al, CA 104(5):33928c (1985). *
Kosuge et al. CA 104(1):5731q (1985). *
March, Advanced Org. Chem. 3rd Edition, 1985 pp. 312, 313, 334, 335, 348, 413, 491, 788. *
RajanBabu et al, CA 104(23):207092t (1986). *
Sundberg, The Chemistry of Indoles, 1970, pp. 180, 181. *
Wang et al, Chem Abst. 119:138892z (1993). *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0741129A3 (en) * 1995-04-24 1997-05-07 Sumitomo Seika Chemicals Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using it
US5756806A (en) * 1995-04-24 1998-05-26 Sumitomo Seika Chemicals Co., Ltd. Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using the same
CN1061975C (en) * 1995-04-24 2001-02-14 住友精化株式会社 Cyanobenzenesulfenyl halide and process for preparation of 3-substituted Benzisothiazole using the same
EP0741129A2 (en) * 1995-04-24 1996-11-06 Sumitomo Seika Chemicals Co., Ltd. Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using it
US5935960A (en) * 1996-02-13 1999-08-10 Pfizer Inc. Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
US6245766B1 (en) * 1997-12-18 2001-06-12 Pfizer Inc Method of treating psychiatric conditions
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
EA007866B1 (en) * 2002-02-20 2007-02-27 Пфайзер Продактс Инк. Controlled synthesis of ziprasidone and compositions thereof
WO2003070246A1 (en) * 2002-02-20 2003-08-28 Pfizer Products Inc. Controlled synthesis of ziprasidone and compositions thereof
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US20070238738A1 (en) * 2003-06-03 2007-10-11 Entire Interest Crystalline ziprasidone HCI and processes for preparation thereof
US7678799B2 (en) 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
US20050059680A1 (en) * 2003-06-03 2005-03-17 Anna Balanov Crystalline ziprasidone HCI and processes for preparation thereof
US20080090835A1 (en) * 2003-06-03 2008-04-17 Teva Pharmaceuticals Usa, Inc. For Barbados Polymorphic forms of ziprasidone HCl and processes for their preparation
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
US20050143397A1 (en) * 2003-10-24 2005-06-30 Gideon Pilarsky Processes for preparation of ziprasidone
US20070078143A1 (en) * 2003-11-28 2007-04-05 Wockhardt Limited Method for preparing Ziprasidone monohydrochloride-hydrate
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
US20080091018A1 (en) * 2003-12-18 2008-04-17 Teva Pharmaceuticals Usa, Inc. Polymorphic form B2 of ziprasidone base
US20080091019A1 (en) * 2003-12-18 2008-04-17 Teva Pharmaceuticals Usa, Inc. Polymorphic form B2 of Ziprasidone base
US20060089502A1 (en) * 2004-10-27 2006-04-27 Sundaram Venkataraman Ziprasidone process
US7777037B2 (en) 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
US20080214566A1 (en) * 2005-02-11 2008-09-04 Judith Aronhime Amorphous ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
WO2008090048A2 (en) 2007-01-26 2008-07-31 Basf Se 3-amino-1,2-benzisothiazole compounds for combating animal pest ii

Also Published As

Publication number Publication date
FI956279A0 (en) 1995-12-27
CA2166203C (en) 2001-04-24
ATE277041T1 (en) 2004-10-15
DK0706524T3 (en) 2005-01-31
PT706524E (en) 2005-03-31
JPH08506354A (en) 1996-07-09
DE69434020D1 (en) 2004-10-28
DE69434020T2 (en) 2005-09-29
EP0706524B1 (en) 2004-09-22
WO1995000510A1 (en) 1995-01-05
ES2227524T3 (en) 2005-04-01
EP0706524A1 (en) 1996-04-17
FI956279A (en) 1995-12-27
JP2667987B2 (en) 1997-10-27
FI119372B (en) 2008-10-31
CA2166203A1 (en) 1995-01-05

Similar Documents

Publication Publication Date Title
US5359068A (en) Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
US4886803A (en) Benzimidazole derivatives
US4737500A (en) 1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and -tetrahydropyridines useful as anxiolytic, psychogeriatric, antidepressant and antischizophrenic agents
US5532372A (en) Imide derivatives, and their production and use
AU641953B2 (en) Benzoxazine derivatives, pharmaceutical compositions containing them and processes for their production
US4680296A (en) Piperidine derivatives and pharmaceutical compositions containing them
US5885988A (en) Benzo g!quinoline derivatives
US5618819A (en) 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
EP0370498A2 (en) Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof
JPS61112063A (en) Analgesic 1,2-benzoisothiazole-3-yl piperazine derivative
US5385916A (en) 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
US5196439A (en) Piperidine compounds useful to treat cerebrovascular diseases
US5166161A (en) 1,3-dicarbonyl compounds and their use
US4435391A (en) Dibenzoxazepine derivative, and pharmaceutical composition comprising the same
EP1446399B1 (en) Piperazine derivatives having sst1 antagonistic activity
US4814345A (en) 1-phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
US4308266A (en) 1,2,3,4-Tetrahydro-2-piperazinyl-naphthalenes for treating hypertension
FR2702214A1 (en) Novel (aryl (alkyl) carbonyl) -heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them
JPH0784471B2 (en) Novel 3-aminochroman spiro compounds, a process for their preparation and pharmaceutical compositions containing them
HU218274B (en) N,n'-bis hydroxyalkyl and alkoxyalkyl-pyridine-2,4-dicarboxylic acid diamide derivatives and pharmaceutical compositions comprising such compounds and process for producing them
CA2156849A1 (en) Benzothiazine derivative
AU705431B2 (en) Indanylpiperidines as melatonergic agents
US4806560A (en) Imidazo[4,5-b]pyridin-2-one derivatives
US5719286A (en) Process and intermediates for bis-aza-bicyclic anxiolytic agents
US5736558A (en) 4-(6-fluoro-1,2-benzisoxazolyl)-1 piperidinyl-propoxy-chromen-4-one-one-derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety

Legal Events

Date Code Title Description
AS Assignment

Owner name: PFIZER INC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:URBAN, FRANK J.;REEL/FRAME:006625/0280

Effective date: 19930625

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:URBAN, FRANK JOHN;REEL/FRAME:006861/0310

Effective date: 19940112

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12